<unk>  is both an inhibitor and a substrate of the transporter proteins P-glycoprotein (Pgp), ABCG2, OATP1B1 and OATP1B3. It is partly degraded by the liver enzymes CYP2B6, CYP2C8 and CYP3A4. Substances that are transported or inactivated by these proteins, or interfere with them, can interact with<unk> . In studies, this has been found for the HIV combination efavirenz/emtricitabine/tenofovir, which reduces the area under the curve (AUC) of<unk>  by about 50%, and the CYP3A4 and Pgp inducer rifampicin, which reduces its AUC by about 80%, rendering it likely ineffective. Digoxin is eliminated by Pgp; its AUC is increased by about 30% in combination with<unk>  and sofosbuvir (although it is not clear which of the two is responsible for this effect). Substances that reduce gastric acid, such as antacids, H2 blockers, and proton pump inhibitors, reduce<unk>  AUC by 20–40%.
Velpatasvir
Ledipasvir
Ombitasvir
Odalasvir
Telaprevir
Elbasvir
Fostemsavir
Saquinavir